X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ABBOTT INDIA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ABBOTT INDIA CIPLA/
ABBOTT INDIA
 
P/E (TTM) x 44.4 41.9 105.9% View Chart
P/BV x 3.9 10.5 37.0% View Chart
Dividend Yield % 0.3 0.6 51.7%  

Financials

 CIPLA   ABBOTT INDIA
EQUITY SHARE DATA
    CIPLA
Mar-17
ABBOTT INDIA
Mar-16
CIPLA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs6226,015 10.3%   
Low Rs4583,707 12.4%   
Sales per share (Unadj.) Rs181.91,236.9 14.7%  
Earnings per share (Unadj.) Rs12.9122.2 10.5%  
Cash flow per share (Unadj.) Rs29.3129.0 22.7%  
Dividends per share (Unadj.) Rs2.0035.00 5.7%  
Dividend yield (eoy) %0.40.7 51.4%  
Book value per share (Unadj.) Rs155.7521.2 29.9%  
Shares outstanding (eoy) m804.5121.25 3,785.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.9 75.6%   
Avg P/E ratio x42.039.8 105.5%  
P/CF ratio (eoy) x18.437.7 48.9%  
Price / Book Value ratio x3.59.3 37.2%  
Dividend payout %15.528.6 54.2%   
Avg Mkt Cap Rs m434,516103,296 420.7%   
No. of employees `00023.03.0 779.5%   
Total wages/salary Rs m26,3383,370 781.6%   
Avg. sales/employee Rs Th6,349.18,891.8 71.4%   
Avg. wages/employee Rs Th1,143.01,140.0 100.3%   
Avg. net profit/employee Rs Th449.3878.3 51.2%   
INCOME DATA
Net Sales Rs m146,30226,284 556.6%  
Other income Rs m2,287504 453.4%   
Total revenues Rs m148,58926,789 554.7%   
Gross profit Rs m24,7583,665 675.4%  
Depreciation Rs m13,229144 9,161.6%   
Interest Rs m1,5948 19,676.5%   
Profit before tax Rs m12,2224,017 304.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7981,421 126.5%   
Profit after tax Rs m10,3542,596 398.8%  
Gross profit margin %16.913.9 121.3%  
Effective tax rate %14.735.4 41.6%   
Net profit margin %7.19.9 71.6%  
BALANCE SHEET DATA
Current assets Rs m87,37014,446 604.8%   
Current liabilities Rs m33,0814,725 700.2%   
Net working cap to sales %37.137.0 100.3%  
Current ratio x2.63.1 86.4%  
Inventory Days Days8751 169.2%  
Debtors Days Days6220 318.6%  
Net fixed assets Rs m111,5671,113 10,024.9%   
Share capital Rs m1,609213 757.2%   
"Free" reserves Rs m123,64510,808 1,144.0%   
Net worth Rs m125,25411,076 1,130.8%   
Long term debt Rs m36,4540-   
Total assets Rs m209,53216,241 1,290.2%  
Interest coverage x8.7497.0 1.7%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.6 43.1%   
Return on assets %5.716.0 35.6%  
Return on equity %8.323.4 35.3%  
Return on capital %8.536.3 23.4%  
Exports to sales %34.20.6 5,564.2%   
Imports to sales %8.312.6 66.0%   
Exports (fob) Rs m50,050162 30,971.3%   
Imports (cif) Rs m12,2033,322 367.3%   
Fx inflow Rs m51,066268 19,054.6%   
Fx outflow Rs m17,6783,927 450.1%   
Net fx Rs m33,388-3,659 -912.4%   
CASH FLOW
From Operations Rs m23,8242,514 947.5%  
From Investments Rs m-13,127-800 1,641.8%  
From Financial Activity Rs m-13,239-803 1,648.8%  
Net Cashflow Rs m-2,478912 -271.7%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 7.9 154.4%  
FIIs % 23.7 0.1 23,700.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.1 153.2%  
Shareholders   161,166 18,270 882.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUVEN LIFE  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 19, 2018 03:33 PM

TRACK CIPLA

CIPLA - TTK HEALTHCARE COMPARISON

COMPARE CIPLA WITH

MARKET STATS